Código QR (código de barras bidimensional)

Real-world Persistence on Selexipag for Pulmonary Arterial Hypertension in Canada

Background: Safety and tolerability of selexipag in pulmonary arterial hypertension (PAH) was demonstrated in a phase 3 clinical trial. In this trial, up to 14% of patients receiving selexipag over a median period of 70 weeks prematurely discontinued therapy due to adverse events. However, no data a...

ver descrição completa

Na minha lista:
Principais autores: Jason Weatherald, MD, Steeve Provencher, MD, Jillian Murray, MPH, Matthew Badin, MBA, MSc, Shane Golden, MSc, Lisa Mielniczuk, MD, John Swiston, MD, Chang Zhang, PhD, Cindy Y.Y. Yip, PhD, Jean-Claude Mamputu, PhD, Brad Millson, MBS
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2026-02-01
coleção:CJC Open
Assuntos:
selexipag
persistence
pulmonary arterial hypertension
Canada
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2589790X2500647X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados